Posted by Michael Wonder on 12 Aug 2021
NICE draft guidance recommends abemaciclib for advanced breast cancer
12 August 2021 - NICE has today published draft guidance which recommends a twice daily pill abemaciclib (Verzenios; Eli Lilly) as an option for adults with a type of breast cancer called hormone receptor-positive, HER2 negative breast cancer which has spread to other parts of the body.
The positive recommendation follows an improved patient access scheme from Eli Lilly.
This, taken together with further economic modelling data provided by the company, means that abemaciclib can now be recommended as a cost effective use of NHS resources.
